AXSM Relative Valuation
AXSM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, AXSM is overvalued; if below, it's undervalued.
Historical Valuation
Axsome Therapeutics Inc (AXSM) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -22.13. The fair price of Axsome Therapeutics Inc (AXSM) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：148.04
Fair
-101.47
PE
1Y
3Y
5Y
Trailing
Forward
423.55
EV/EBITDA
Axsome Therapeutics Inc. (AXSM) has a current EV/EBITDA of 423.55. The 5-year average EV/EBITDA is -20.04. The thresholds are as follows: Strongly Undervalued below -197.30, Undervalued between -197.30 and -108.67, Fairly Valued between 68.59 and -108.67, Overvalued between 68.59 and 157.22, and Strongly Overvalued above 157.22. The current Forward EV/EBITDA of 423.55 falls within the Strongly Overvalued range.
-136.41
EV/EBIT
Axsome Therapeutics Inc. (AXSM) has a current EV/EBIT of -136.41. The 5-year average EV/EBIT is -23.82. The thresholds are as follows: Strongly Undervalued below -69.14, Undervalued between -69.14 and -46.48, Fairly Valued between -1.16 and -46.48, Overvalued between -1.16 and 21.50, and Strongly Overvalued above 21.50. The current Forward EV/EBIT of -136.41 falls within the Strongly Undervalued range.
8.58
PS
Axsome Therapeutics Inc. (AXSM) has a current PS of 8.58. The 5-year average PS is 1435.53. The thresholds are as follows: Strongly Undervalued below -10900.17, Undervalued between -10900.17 and -4732.32, Fairly Valued between 7603.38 and -4732.32, Overvalued between 7603.38 and 13771.23, and Strongly Overvalued above 13771.23. The current Forward PS of 8.58 falls within the Historic Trend Line -Fairly Valued range.
151.99
P/OCF
Axsome Therapeutics Inc. (AXSM) has a current P/OCF of 151.99. The 5-year average P/OCF is -125.23. The thresholds are as follows: Strongly Undervalued below -2401.73, Undervalued between -2401.73 and -1263.48, Fairly Valued between 1013.02 and -1263.48, Overvalued between 1013.02 and 2151.28, and Strongly Overvalued above 2151.28. The current Forward P/OCF of 151.99 falls within the Historic Trend Line -Fairly Valued range.
122.14
P/FCF
Axsome Therapeutics Inc. (AXSM) has a current P/FCF of 122.14. The 5-year average P/FCF is 117.18. The thresholds are as follows: Strongly Undervalued below -1237.51, Undervalued between -1237.51 and -560.16, Fairly Valued between 794.53 and -560.16, Overvalued between 794.53 and 1471.87, and Strongly Overvalued above 1471.87. The current Forward P/FCF of 122.14 falls within the Historic Trend Line -Fairly Valued range.
Axsome Therapeutics Inc (AXSM) has a current Price-to-Book (P/B) ratio of 101.02. Compared to its 3-year average P/B ratio of 45.07 , the current P/B ratio is approximately 124.11% higher. Relative to its 5-year average P/B ratio of 47.38, the current P/B ratio is about 113.20% higher. Axsome Therapeutics Inc (AXSM) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -3.36%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -4.58% , the current FCF yield is about -100.00% lower.
101.02
P/B
Median3y
45.07
Median5y
47.38
-1.36
FCF Yield
Median3y
-3.36
Median5y
-4.58
Competitors Valuation Multiple
The average P/S ratio for AXSM's competitors is , providing a benchmark for relative valuation. Axsome Therapeutics Inc Corp (AXSM) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 63.22%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of AXSM increased by 74.97% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -19.02 to -31.75.
The secondary factor is the Revenue Growth, contributed 63.22%to the performance.
Overall, the performance of AXSM in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Axsome Therapeutics Inc (AXSM) currently overvalued or undervalued?
What is Axsome Therapeutics Inc (AXSM) fair value?
How does AXSM's valuation metrics compare to the industry average?
What is the current P/B ratio for Axsome Therapeutics Inc (AXSM) as of Dec 05 2025?
What is the current FCF Yield for Axsome Therapeutics Inc (AXSM) as of Dec 05 2025?
What is the current Forward P/E ratio for Axsome Therapeutics Inc (AXSM) as of Dec 05 2025?